Neuralstem (NASDAQ: CUR) and Innocoll (NASDAQ:INNL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.


This table compares Neuralstem and Innocoll’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuralstem -154,347.81% -148.94% -84.85%
Innocoll -1,051.20% N/A -138.53%

Earnings and Valuation

This table compares Neuralstem and Innocoll’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neuralstem $20,000.00 1,249.88 -$21.07 million N/A N/A
Innocoll N/A N/A N/A ($1.66) -1.42

Innocoll has lower revenue, but higher earnings than Neuralstem.

Insider and Institutional Ownership

7.1% of Neuralstem shares are held by institutional investors. Comparatively, 34.2% of Innocoll shares are held by institutional investors. 19.3% of Neuralstem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Neuralstem and Innocoll, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuralstem 0 0 0 0 N/A
Innocoll 0 2 1 0 2.33

Neuralstem presently has a consensus target price of $1.91, suggesting a potential upside of 15.76%. Innocoll has a consensus target price of $3.00, suggesting a potential upside of 27.66%. Given Innocoll’s higher probable upside, analysts plainly believe Innocoll is more favorable than Neuralstem.


Innocoll beats Neuralstem on 5 of the 8 factors compared between the two stocks.

About Neuralstem

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

About Innocoll

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with's FREE daily email newsletter.